EUCTR2014-002128-28-AT
Active, not recruiting
Phase 1
A Prospective Multicenter Phase 2/3 Clinical Trial with Sodium Thiosulfate for the Treatment of Calciphylaxis
Dr. F. Köhler Chemie GmbH0 sites40 target enrollmentDecember 4, 2014
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Calciphylaxis
- Sponsor
- Dr. F. Köhler Chemie GmbH
- Enrollment
- 40
- Status
- Active, not recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •(1\)All patients \= 18 years
- •(2\)Male or female HD patients with a diagnosis of calciphylaxis. (Patients on peritoneal dialysis or patients with the requirement for renal replacement therapy, who are diagnosed with calciphylaxis, may be switched to HD and included in the study after switching).
- •(3\)Able to understand character and individual consequences of the clinical trial and to provide written informed consent to participate in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 20
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 20
Exclusion Criteria
- •(1\) Sodium metabisulfite hypersensitivity, among others the history of bronchial asthma due to known sodium metabisulfite hypersensitivity
- •(2\)Females who are pregnant (positive pregnancy test at screening or during study phase), lactating, or if having reproductive potential (being not post\-menopausal (no menses for 12 months without an alternative medical cause) or surgically sterilized) are considered potentially ineligible with respect to use highly effective methods of birth control throughout the study, which are also described in detail in the Patient Inform Consent Form. (Of note, STS has been demonstrated not to cross the blood\-placenta barrier in gravid eves (Graeme et al., 1999\); therefore we regard fetal damage also as unlikely in humans).
- •(3\)Patients who have participated in any other investigational studies within 30 days previous to enrollment
- •(4\)History of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or any history of drug abuse or addiction within 12 months of study enrolment.
- •(5\) Good response to conventional treatment.
- •(6\) Life expectancy less than 4 months in the judgement of the investigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Phase 2/3 Clinical Trial with Sodium Thiosulfate for the Treatment of CalciphylaxisCalciphylaxisMedDRA version: 20.0Level: PTClassification code 10051714Term: CalciphylaxisSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2014-002128-28-DEDr. F. Köhler Chemie GmbH40
Completed
Phase 2
A clinical trial with Sodium Thiosulfate for the treatment of CalciphylaxisCalciphylaxisCirculatory SystemISRCTN73380053Dr. F. Köhler Chemie GmbH (Germany)5
Not yet recruiting
Phase 3
REALISE: Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and EffectivenessSoil-transmitted helminthsPaediatricsPACTR202402529220760aboratorios Liconsa SA20,000
Active, not recruiting
Phase 1
Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC) after preoperative chemotherapy in patients with peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junctioPeritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junctionMedDRA version: 20.0Level: LLTClassification code 10042080Term: Stomach cancerSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10042081Term: Stomach cancer in situSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2006-006088-22-DEKlinik für Chirurgie, Charité Campus Virchow-Klinikum180
Completed
Phase 3
Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC)after preoperative chemotherapy in patients with peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junctioMedDRA - 10042080 (stomach cancer)C16D00.2C78.6C79Malignant neoplasm of stomachStomachSecondary malignant neoplasm of retroperitoneum and peritoneumSecondary malignant neoplasm of other and unspecified sitesDRKS00003078Charité Campus Charité Mitte105